Puma Biotechnology (PBYI) Scheduled to Post Earnings on Thursday

Puma Biotechnology (NASDAQ:PBYI) is scheduled to post its Q2 2019 quarterly earnings results after the market closes on Thursday, August 8th. Analysts expect Puma Biotechnology to post earnings of ($0.90) per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.43. Puma Biotechnology had a negative return on equity of 245.22% and a negative net margin of 35.01%. The business had revenue of $99.10 million for the quarter, compared to the consensus estimate of $67.25 million. During the same period in the previous year, the business earned $0.03 EPS. Puma Biotechnology’s revenue was up 49.0% compared to the same quarter last year. On average, analysts expect Puma Biotechnology to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

NASDAQ:PBYI opened at $9.14 on Wednesday. The stock’s fifty day moving average price is $11.33. Puma Biotechnology has a 52-week low of $8.45 and a 52-week high of $54.20. The company has a debt-to-equity ratio of 4.08, a quick ratio of 2.50 and a current ratio of 2.53. The firm has a market cap of $352.91 million, a P/E ratio of -3.06 and a beta of 1.73.

Several research analysts have issued reports on the company. BidaskClub raised Puma Biotechnology from a “strong sell” rating to a “sell” rating in a report on Thursday, August 1st. ValuEngine raised Puma Biotechnology from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Citigroup downgraded Puma Biotechnology from a “buy” rating to a “neutral” rating and set a $24.00 price objective on the stock. in a report on Friday, May 10th. Cowen reaffirmed a “hold” rating and set a $28.00 price objective on shares of Puma Biotechnology in a report on Friday, July 5th. Finally, JPMorgan Chase & Co. reduced their price objective on Puma Biotechnology from $27.00 to $19.00 and set an “underweight” rating on the stock in a report on Friday, May 10th. Four investment analysts have rated the stock with a sell rating and nine have assigned a hold rating to the stock. Puma Biotechnology currently has a consensus rating of “Hold” and a consensus price target of $27.00.

In other Puma Biotechnology news, insider Alan H. Auerbach sold 12,715 shares of the company’s stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $9.98, for a total transaction of $126,895.70. Following the completion of the sale, the insider now owns 4,189,525 shares in the company, valued at approximately $41,811,459.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 14,299 shares of company stock valued at $146,360 in the last quarter. Corporate insiders own 21.80% of the company’s stock.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous).

Further Reading: How Important is Technical Analysis of Stocks

Earnings History for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.